Pfizer Posts Solid Earnings Boost and Diversification Efforts

3 months ago

Nathan Hager

"PFE is your ticker for the pharmaceutical stock, vaccine maker, whatever you want to call it. Those shares higher by 1.1%. So, it's not doom and gloom everywhere. Uh shares are trading at about $25 a share approximately, give or take a couple of cents. Their earnings are coming in because they've boosted profit. There are looking for diversifying, remember their portfolio of drugs. A big piece of that is their approach around Metera, something that they're in a bidding war with the likes of Novo Nordisk on. So nevertheless, they are talking about boosting profit despite some of their Covid vaccines seeing less demand. And of course, that is something that was largely expected in some of these earnings. Their full year adjusted EPS also coming in hotter than what the street expected. So some good news there."

Pfizer's earnings beat and diversification strategy, including a competitive bidding war for Metera, are pushing its stock higher, serving as a positive indicator despite softer vaccine demand.

Related Stocks